BackVirax Biolabs Group Overview

Virax Biolabs Group Long Term Debt

Virax Biolabs Group's long-term debt is $300K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$304808.00
↑ 4.55% YoYΔ $13265.00 vs prior year quarter

Peer average

Loading

Virax Biolabs Group Long Term Debt History

Loading

Virax Biolabs Group vs. peers: Long Term Debt Comparison

Loading

Virax Biolabs Group Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Virax Biolabs Group (VRAX) FAQ

As of the most recent data (March 2026), VRAX shows a long-term debt of $300K. That compares with $290K in the prior-year period — up 4.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VRAX's long-term debt is now $300K (was $290K) — a 4.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Virax Biolabs Group is outperforming or lagging.

Tracking VRAX's long-term debt over time shows whether Virax Biolabs Group is scaling, shrinking, or reshaping that part of the business. The current reading is $300K That compares with $290K in the prior-year period — up 4.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Virax Biolabs Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $300K) with ownership activity and broader fundamentals.